Arrhythmias & electrophysiology

Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace)

EuropacePublished Randomised controlled trial

An erratum to this article was published (Europace, 7 Oct 2025 ↗)

Authors' conclusion

In patients, predominantly with preserved LVEF, narrow QRS, and HVPB, superiority of implanting BiVPDs compared with RVPDs could not be proven.

Study context

Population
Patients anticipated to require frequent ventricular pacing, predominantly with preserved LV ejection fraction (LVEF) and narrow QRSrandomized, analysed
Participants
1,810 patients
Comparison
Biventricular (BiV) pacing device vs right ventricular (RV) pacing device
  • BiVn = 902
  • RVn = 908reference
Primary endpoint
Co-primary: (i) composite of time to death or first HF hospitalization; (ii) survival time
Follow-up
Mean 68.8 months
Methodological detailsmulticentre, single-blinded (patients), parallel group
  • Multicentre
  • Single-blinded (patients)
  • Parallel group

Primary result

As reported in the abstract

BiV

346

events

RV

363

events

BiV vs RVHazard ratio (95% CI)P value
Death or first HF hospitalization
0.878(0.756–1.020)
P = 0.0882
Mortality
0.926(0.789–1.088)
P = 0.3492

Original publication

Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace). Europace. Published 19 March 2025. doi:10.1093/europace/euaf029

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.